uniQure Q2 2026: FDA Greenlights AMT-130 BLA Path, Cash Runway Extended to 2030
QURE has more than doubled off its 52-week low of $8.73.
Summary
uniQure's Q2 2026 filing reveals FDA alignment on an accelerated approval path for its Huntington's disease gene therapy AMT-130, with a BLA submission planned for Q3 2026. Positive early data for AMT-260 and AMT-191 were also reported, and the company ended the quarter with $810.3 million in cash, extending its runway into 2030.
Key Events · Earnings and Guidance · QURE
-
FDA Aligns on AMT-130 BLA Path
In June 2026, the FDA agreed that a BLA submission for AMT-130 under accelerated approval is reasonable, with submission expected in Q3 2026. Prior to filing, the agency seeks alignment on a confirmatory study design.
-
Q2 2026 Financial Results
Revenue of $5.8 million was offset by a net loss of $81.1 million. As of June 30, 2026, cash, cash equivalents, and investment securities totaled $810.3 million, providing runway into 2030.
-
AMT-260 Phase I/IIa Preliminary Data
In the low-dose cohort, three of six patients achieved a 79% to 100% reduction in disabling seizures during months four through six of follow-up. No serious adverse events related to AMT-260 were reported.
-
AMT-191 Fabry Disease Program Update
Dose-dependent α-Gal A activity was observed across 11 patients, all of whom have been withdrawn from enzyme replacement therapy. Dosing in the mid- and high-dose cohorts has been paused pending evaluation of asymptomatic liver enzyme elevations.
Analysis · QURE · Life Sciences
The Q2 2026 report from uniQure packs several positive catalysts. Most notably, the FDA has agreed that a BLA submission for AMT-130 under accelerated approval is reasonable, with filing expected in Q3 2026 — a major de-risking event following earlier regulatory setbacks. Encouraging early data also emerged for AMT-260 in epilepsy, alongside updated AMT-191 Fabry disease results. Financially, the company closed the quarter with $810.3 million in cash and investments, extending its runway into 2030, bolstered by a $242.7 million follow-on offering in June. Together, the regulatory progress, clinical data, and strengthened balance sheet significantly enhance the investment thesis.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35% of the 1333 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QURE was trading at $38.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $8.73 to $71.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.